Novartis Kisqali 200 mg film-coated tablets

Kisqali is a specialized pharmaceutical medication developed by Novartis, primarily used for the treatment of certain types of breast cancer. The active ingredient, Ribociclib, was initially developed by Novartis Institutes for BioMedical Research in collaboration with Astex Pharmaceuticals.

As a high-tech biopharmaceutical product, Kisqali is manufactured in Novartis' advanced facilities, with significant production stages occurring in Switzerland, where the company is headquartered. Novartis maintains a global leadership position in innovative medicines and oncology, ensuring the global distribution of this treatment through its extensive network of subsidiaries. The brand remains under the total ownership of Novartis AG.